Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Ischemic Stroke Subject or subject's LAR has provided informed consent. 2. ≥18 years of age. 3. AIS diagnosis including: 1. CTA with evidence of anterior circulation large artery occlusion (i.e., ICA terminus, M1, M2, A1, A2). 2. Large volumes of absolute hypo-perfused mismatch tissue (Tmax >10 s lesion - rCBF<30% lesion) >50 mL and core volumes ≤70 mL on CT Perfusion (CTP) and/or score 5. 3. Thrombolysis in Cerebral Infarction 0-1 flow in the intracranial internal carotid artery, M1 or M1-M2 segment of the middle cerebral artery, or carotid terminus confirmed by CTA and CTP that is accessible to thrombectomy. 4. Last seen well ≤24 hours prior to start of investigational product (IP) infusion. Note: Onset is defined as the time point when symptoms first began, or if unknown, the last time point when the subject reported or was observed having normal neurological function. 4. Modified Rankin Score ≤2, prior to the onset of symptoms (self-reported or family/caregiver reported). 5. Subject has an anticipated life expectancy of at least three months, in the opinion of the Investigator. 6. Subject and caregiver are available for protocol required follow-up visits. 7. Contraception and pregnancy: 1. Male subjects, and females of childbearing potential (subjects and female partners of male subjects who are ovulating, premenopausal, and not surgically sterile) must use a highly effective method of contraception consistently and correctly during study participation and up to 90 days following PP-007 infusion. Highly effective methods of contraception are those that, either alone or in combination, result in a failure rate of <1% per year when used consistently and correctly, including: i. Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (i.e., oral, intravaginal, or transdermal). ii. Progesterone-only hormonal contraception associated with inhibition of ovulation (i.e., oral, injectable, or implantable). iii. Intrauterine device, intrauterine hormone-releasing system, or bilateral tubal occlusion. iv. Male sterilization performed more than six months prior to Screening. v. Sexual abstinence. c. Female subjects of non-childbearing potential must be either surgically sterile (hysterectomy, bilateral tubal ligation, salpingectomy, and/or bilateral oophorectomy at least 26 weeks before Screening) or postmenopausal, defined as spontaneous amenorrhea for at least 12 months. d. Male subjects must abstain from sperm donation during study participation and up to 90 days following PP-007 infusion. e. Female subjects of childbearing potential must have negative results for the pregnancy test at Screening/Baseline  < 5 on NCCT. 2. Bilateral middle cerebral artery stroke. 3. Evidence of intracranial hemorrhage, including subarachnoid hemorrhage, on initial CTA/CTP, or history of intracranial hemorrhage within the last 30 days. 4. Subjects who have received or are scheduled to receive tPA use for current stroke. 5. Pre-existing neurological or psychiatric disease that would confound neurological or functional evaluations in the opinion of the Investigator. 6. A seizure at stroke onset that precludes obtaining at accurate Screening NIHSS and mRS assessment. 7. History of severe head injury within 90 days of Baseline with residual neurological deficit at the time of AIS. 8. Clinically significant heart disease including: a. Symptoms or ECG evidence of acute myocardial infarction or unstable angina. b. Cardiac arrhythmia associated with hemodynamic instability. c. Heart failure (New York Heart Association Class III or IV) or known ejection fraction <30%. d. ECG with second or third-degree heart block in the absence of a permanent pacemaker. 9. Refractory BP (systolic >200 and/or diastolic >120 mmHg). 10. Confirmed diagnosis of septic embolus or bacterial endocarditis within the past six months. 11. Aortic dissection. 12. Known history of arterial tortuosity, pre-existing stent, and/or other arterial disease which would prevent the device from reaching the target vessel and/or preclude safe recovery of a device. 13. Contraindication to radiographic imaging procedures including: a. Known hypersensitivity to radiographic contrast agents. b. Known renal insufficiency precluding repeated contrast administration. 14. Prior treatment (within the last 30 days) or planned concurrent treatment with an investigational medication or device. 15. Blood glucose <50 mg/dL (2.78 mmol) or >400 mg/dL (22.20 mmol) that is not responsive to appropriate treatment at Baseline. 16. Known bleeding disorder (e.g., coagulopathy or thrombocytopenia). 1. Platelet count <50,000/μL at Baseline. 2. Prothrombin Time (International Normalization Ratio [INR]) ≥2 and/or activated partial tromboplastin time (aPTT) ≥40 seconds at Baseline. 3. Any anticoagulants within the previous 48 hours. 4. Any dual antiplatelet agents (e.g., aspirin plus clopidogrel) within the previous 48 hours. 17. History or current evidence of renal or hepatic disease including: a. Documented renal insufficiency (serum creatinine >3.0 × ULN). b. History of liver disease (i.e., alanine transaminase [ALT] and/or Aspartate transaminase (AST) >2 × ULN and/or conjugated bilirubin >1.5 mg/dL). Note: A subject without history or current evidence of renal or hepatic disease does not require creatinine, ALT, AST, or bilirubin results to be available prior to enrollment. 18. Mass effect or intracranial mass on NCCT defined as: 1. Significant mass effect with midline shift ≥8 mm. 2. Evidence of intracranial mass (except for small non-clinically significant meningioma based on the Investigator's discretion). 19. Employee of Prolong Pharmaceuticals or its designated clinical research organization or an employee or relative of the Investigator. 20. Any condition or situation which may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study in the opinion of the Investigator